RxDoctor Payments Data

Sarah Ledger, DO

Family Medicine · Mt Pleasant, IANPI 1811195290

Payments from drug & device makers

$316in general payments, 2019–2025

Across 8 payments — averaging $39.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$130
  • Pfizer$118
  • Dexcom, Inc.$39
  • Lilly USA, LLC$28

What the payments were for

  • Food & beverage$30496%
  • Education$124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$130
Pfizer1$118
Dexcom, Inc.2$39
Lilly USA, LLC2$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$316 in reported general payments places this provider in the 65th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$316,911
Medicare patients
568
Services billed
4,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$101,832
OzempicSemaglutide93$91,720
EliquisApixaban96$62,916
MounjaroTirzepatide42$43,670
TrulicityDulaglutide32$35,375
Stiolto RespimatTiotropium Br/Olodaterol Hcl34$21,935
Combivent RespimatIpratropium/Albuterol Sulfate19$15,533
Tresiba Flextouch U-100Insulin Degludec31$14,257
JanuviaSitagliptin Phosphate20$13,420
Varenicline Tartrate12$3,524
Colestipol Hcl43$3,378
Duloxetine Hcl54$3,082
Levothyroxine Sodium396$2,842
Ursodiol15$2,800
DilantinPhenytoin Sodium Extended12$2,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$130$91,72093 claims
Lilly USA, LLCMounjaro, Trulicity, Humulin N$28$80,92886 claims
PfizerEliquis, Dilantin$118$65,587108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Mt Pleasant

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →